Serial Bronchoalveolar Lavage Fluid Galactomannan and Treatment Response in Invasive Pulmonary Aspergillosis

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2024 Apr 1

PMID 38560609

Authors

Daniel Z P Friedman

Elitza S Theel

Randall C Walker

Holenarasipur R Vikram

Raymund R Razonable

Paschalis Vergidis

Affiliations

Soon will be listed here.

Abstract

We studied patients diagnosed with aspergillosis based on positive bronchoalveolar lavage (BAL) galactomannan (GM) who had follow-up BAL sampling within 180 days. GM trend and clinical outcome were concordant in only 60% (30/50). While useful for the initial diagnosis, BAL GM trending does not always correlate with treatment response.

References

Pfeiffer C, Fine J, Safdar N . Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006; 42(10):1417-27. DOI: 10.1086/503427. View

Mennink-Kersten M, Donnelly J, Verweij P . Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004; 4(6):349-57. DOI: 10.1016/S1473-3099(04)01045-X. View

Shikano K, Abe M, Shiko Y, Tsushima K, Yoshioka K, Ishiwata T . What are the factors affecting the recovery rate of bronchoalveolar lavage fluid?. Clin Respir J. 2021; 16(2):142-151. PMC: 9060131. DOI: 10.1111/crj.13462. View

Segal B, Herbrecht R, Stevens D, Ostrosky-Zeichner L, Sobel J, Viscoli C . Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008; 47(5):674-83. PMC: 2671230. DOI: 10.1086/590566. View

Donnelly J, Chen S, Kauffman C, Steinbach W, Baddley J, Verweij P . Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019; 71(6):1367-1376. PMC: 7486838. DOI: 10.1093/cid/ciz1008. View

Mercier T, Castagnola E, Marr K, Wheat L, Verweij P, Maertens J . Defining Galactomannan Positivity in the Updated EORTC/MSGERC Consensus Definitions of Invasive Fungal Diseases. Clin Infect Dis. 2021; 72(Suppl 2):S89-S94. DOI: 10.1093/cid/ciaa1786. View

de Heer K, Gerritsen M, Visser C, Leeflang M . Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2019; 5:CD012399. PMC: 6526785. DOI: 10.1002/14651858.CD012399.pub2. View

DHaese J, Theunissen K, Vermeulen E, Schoemans H, De Vlieger G, Lammertijn L . Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol. 2012; 50(4):1258-63. PMC: 3318563. DOI: 10.1128/JCM.06423-11. View

Leeflang M, Debets-Ossenkopp Y, Wang J, Visser C, Scholten R, Hooft L . Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev. 2015; (12):CD007394. PMC: 6483812. DOI: 10.1002/14651858.CD007394.pub2. View

10.

Koo S, Bryar J, Baden L, Marty F . Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol. 2010; 48(4):1255-60. PMC: 2849624. DOI: 10.1128/JCM.02281-09. View

11.

Neofytos D, Railkar R, Mullane K, Fredricks D, Granwehr B, Marr K . Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis. PLoS One. 2015; 10(6):e0129022. PMC: 4480423. DOI: 10.1371/journal.pone.0129022. View